


## Sample Screenshots of Antibody Database as of June 30, 2024





**Login**

---

Username:

Password:

Report Code:






Remember Username?  
[Forgot Password?](#)

---

If you have problems logging in, please contact us at  
[support@lamerie.com](mailto:support@lamerie.com)

 Print

**Projects**

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33287	2024-06-20	TSLP Antibody	Thymic stromal lymphopoietin (TSLP) inhibitor	Rec monoclonal antibody	Antibody	Perseus Therapeutics	United States	Dermatology	Prevention of hair loss in cancer	Preclinical	
33286	2024-06-20	CD45-ADC	CD45 and toxic payload	Rec monoclonal antibody conjugated to cytotoxic payload	Antibody	Cimeio Therapeutics	United States	Oncology	Hematologic malignancies in combination with CD45-engineered (shielded) hematopoietic stem cells (HSPCs)	Preclinical	
33285	2024-06-20	PHN-010	Undisclosed novel target highly overexpressed in a wide range of solid tumors and DNA topoisomerase I inhibitor as cytotoxic payload	Rec monoclonal antibody conjugated to a novel topoisomerase I inhibitor agent with DAR of 8	Antibody	Pheon Therapeutics	United States	Oncology	Solid tumors	0	
33284	2024-06-20	BDC-4182	Claudin 18.2 (CLDN18.2) and toll-like receptor (TLR) 7/8 agonist	Rec humanized monoclonal antibody conjugated to TLR7/8 agonist	Antibody	Bolt Biotherapeutics	United States	Oncology	Solid tumors	0	
33283	2024-06-18	TOUR006; TOUR-006; PF-04236921; ...	Interleukin-6 (IL-6) antagonist	Rec fully human IgG2 monoclonal antibody	Antibody	Tourmaline Bio (from Pfizer)	United States	Cardiovascular, blood & acute care	Atherosclerotic cardiovascular disease (ASCVD)	II	

**Search**

ProfoundBio  
   
 Any Word  All Words  Exact Phrase  Advanced Search  
 Target:   
 Technology:

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Therapeutic Area**

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33227	2024-04-11	PRO1286; PRO-1286	Epidermal growth factor receptor (EGF-R) and c-Met and cytotoxic payload	Rec monovalent bispecific IgG1 monoclonal antibody conjugated to topoisomerase 1 inhibitor-based linker-drug, sesutecan with DAR of 8	Antibody	Genmab (acquired Profoundbio)	Denmark	Oncology	Solid tumors	0	
33096	2024-04-11	PRO1107; PRO-1107	Protein tyrosine kinase-7 (PTK-7) and microtubule inhibitor	Rec humanized monoclonal antibody conjugated via novel highly hydrophilic linker to monomethylauristatin E (MMAE) (DAR of 8)	Antibody	Genmab (acquired Profoundbio)	Denmark	Oncology	advanced solid tumors, including non-small cell lung, breast, and ovarian cancer.	1	
									Metastatic renal cell		

Search

ProfoundBio

Clear

Any Word  All Words  Exact Phrase  Advanced Search

Target:

Technology:

Id	Last Update	Project	Target
33227	2024-04-11	PRO1286; PRO-1286	Epidermal growth factor receptor (EGF-R) and c-Met and cytotoxic payload
33096	2024-04-11	PRO1107; PRO-1107	Protein tyrosine kinase-7 (PTK7) microtubule inhibitor
31912	2024-04-11	PRO1160; PRO-1160	CD70 and cytotoxic payload
31911	2024-04-11	Rinatabart sesutecan (Rina-S); PRO1184; PRO-1184 (Global study)	Folate receptor and topoisomerase inhibitor

View Project [33227]

Print

Last Update: 2024-04-11

PRO1286; PRO-1286

**Target:** Epidermal growth factor receptor (EGF-R) and c-Met and cytotoxic payload

**Class of Compound:** Rec monovalent bispecific IgG1 monoclonal antibody conjugated to topoisomerase 1 inhibitor-based linker-drug, sesutecan with DAR of 8

**Category:** Antibody

**Company:** Genmab (acquired Profoundbio)

**Territory:** Denmark

**Therapeutic Area:** Oncology

**Indication:** Solid tumors

**Phase:** 0

**Administration:**

**Drug Delivery:**

**Status:** Active

**Approval US:**

**Approval UE:**

**Approval RoW:**

**Antibody Tech:**

**Protein Tech:**

**DNA Tech:**

**RNA Tech:**

**Cell Tech:**

**Vaccine Tech:**

**Partnering**

News

Date	Title	Comments
2024-04-11	<a href="#">Genmab PR Apr 03, 2024</a>	Genmab and ProfoundBio have entered into a definitive agreement for Genmab to acquire ProfoundBio. Genmab will acquire ProfoundBio for USD 1.8 billion in cash. The acquisition will give Genmab worldwide rights to ProfoundBio's portfolio of next-generation ADCs, which consists of three clinical and multiple preclinical programs including PRO1160, an ADC targeting CD70; PRO1107, an ADC targeting PTK7; and PRO1286, a bispecific ADC targeting EGFR and cMET. PRO1286, a bi-specific ADC, is anticipated to enter the clinic in 2024 ( <a href="#">source</a> ). PRO1286 is comprised of a monovalent bispecific human IgG1 (dubbed as "Bsab") with fine-tuned affinity on EGFR and cMET, and the proprietary topoisomerase 1 inhibitor-based linker-drug, sesutecan ( <a href="#">source</a> ).

Files

No files

Print

Export

Export

Indication	Phase	
Solid tumors	0	
advanced solid tumors, including non-small cell lung, breast, and ovarian cancer.		
Metastatic renal cell carcinoma, metastatic or relapsed nasopharyngeal carcinoma, or advanced non-Hodgkin lymphoma	I/II	
Ovarian, endometrial, breast, non-small cell lung cancers and mesothelioma	I/II	

Search

Print Export Export

Search

Clear

Any Word  All Words  Exact Phrase  Advanced Search

Target: All Targets

Technology: All Technologies

- Territory**
- All Countries
  - Aaland Islands
  - Afghanistan
  - Albania
  - Algeria
  - American Samoa
  - Andorra
  - Angola

- Therapeutic Area**
- Infectious & toxicology
  - Metabolism & endocrine
  - Neurology & psychiatry
  - Oncology
- Phase**
- All Phases
  - Market
  - sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33260	2024-04-22	BAN2802; BAN-2802	Not disclosed target	Rec monoclonal antibody using BrainTransporter™ technology	Antibody	BioArctic Neuroscience & Eisai	Japan,Sweden	Neurology & psychiatry	Alzheimer's disease	Preclinical	
33226	2024-04-08	E2025; E-2025	Erythropoietin-producing hepatocellular receptor A4 (EphA4) antagonist	Rec monoclonal antibody	Antibody	Eisai	Japan	Neurology & psychiatry	Alzheimer's disease (AD)	I	
33211	2024-03-28	CM383; CM-383	Amyloid beta protofibrils	Re monoclonal antibody	Antibody	Keymed Biosciences	China	Neurology & psychiatry	Alzheimer's disease	CTA	
33200	2024-03-25	SSS40; SSS-40	Nerve growth factor (NGF)	Rec humanized monoclonal antibody	Antibody	3SBio (Shenyang Sunshine Pharmaceuticals)	China	Neurology & psychiatry	Moderate to severe bone metastasis cancer pain	I	
33178	2024-03-21	MEDI0618; MEDI-0618	Protease-Activated Receptor-2 (PAR2) antagonist	Rec monoclonal antibody	Antibody	AstraZenec	United Kingdom	Neurology & psychiatry	Migraine	I	
33153	2024-03-18	Mezagitamab; TAK-079	CD38 (for CD38+ cell depletion)	Rec fully human, non-agonistic IgG1 cytolytic monoclonal antibody. SC	Antibody	Takeda Pharmaceutical Co	Japan	Neurology & psychiatry	Primary immune thrombocytopenia	II	

**Search**

Print Export Export

 Search

Clear

Any Word  All Words  Exact Phrase  Advanced Search

Target: **Complement C5 Antibodies: Biosimilars** ▾

- All Targets
- Adalimumab (Humira) Biosimilars
- Antibody-Drug-Conjugates (ADC)
- Bevacizumab (Avastin) Biosimilars
- Biosimilar and Biosuperior Therapeutic Antibodies
- Blys, BAFF & APRIL Antagonists
- CD19-Targeted Therapeutics
- CD20 Antibodies: Rituximab Biosimilars and Biobetters/Biosuperiors
- CD25 (IL-2R) Antibodies: Biosimilars and Biosuperiors
- CD30 Antibodies
- Certolizumab pegol (Cimzia) Biosimilars
- Cetuximab (Erbix) Biosimilars
- Complement C5 Antibodies: Biosimilars and Biosuperiors**
- Complement C5 Inhibitors & C5a Receptor Antagonists
- EGF-R (ErbB) Antagonists
- EGF-R Antibodies: Biosimilars and Biosuperiors
- Etanercept (Enbrel) Biosimilars
- FGF-R Agonists & Antagonists
- GM-CSF Antibodies
- Golimumab (Simponi) Biosimilars
- ZU24-U3-25 SSS40; SSS-40 (NGF) antibody

- Territory**
- All Countries
  - Aaland Islands
  - Afghanistan
  - Albania
  - Algeria
  - American Samoa
  - Andorra
  - Angola

- Therapeutic Area**
- All Therapeutic Areas
  - Cardiovascular, blood & acute care
  - Dermatology

- Phase**
- All Phases
  - Market
  - sBLA

Id	Category	Company	Territory	Therapeutic Area	Indication	Phase				
33260	antibody porter™	BioArctic Neuroscience & Eisai	Japan,Sweden	Neurology & psychiatry	Alzheimer's disease	Preclinical				
33226	antibody	Eisai	Japan	Neurology & psychiatry	Alzheimer's disease (AD)	I				
33211	antibody	Keymed Biosciences	China	Neurology & psychiatry	Alzheimer's disease	CTA				
33200	monoclonal antibody	3SBio (Shenyang Sunshine Pharmaceuticals)	China	Neurology & psychiatry	Moderate to severe bone metastasis cancer pain	I				
33178	2024-03-21 MEDI0618; MEDI-0618	Protease-Activated Receptor-2 (PAR2) antagonist	Rec monoclonal antibody	Antibody	AstraZenec	United Kingdom	Neurology & psychiatry	Migraine	I	
33153	2024-03-18 Mezagitamab; TAK-079	CD38 (for CD38+ cell depletion)	Rec fully human, non-agonistic IgG1 cytolytic monoclonal antibody, SC	Antibody	Takeda Pharmaceutical Co	Japan	Neurology & psychiatry	Primary immune thrombocytopenia	II	

**Search**

Print Export Export

Search

Clear

Any Word  All Words  Exact Phrase  Advanced Search

Target:

Technology:

**Territory**

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

**Therapeutic Area**

- All Therapeutic Areas
- Cardiovascular, blood & acute care
- Dermatology

**Phase**

- All Phases
- Market
- sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
32552	2023-07-30	Soliris; eculizumab; H5G1.1	Complement C5 inhibitor	Rec humanized (hybrid IgG2/4) Fc-modified full mab for intravenous administration	Antibody	AstraZeneca (acquired Alexion Pharmaceuticals)	United Kingdom	Neurology & psychiatry	Refractory generalised myasthenia gravis (gMG) in children and adolescents aged six to 17 years who are anti-acetylcholine receptor (AChR) antibody-positive (Ab+)	Market	
32523	2023-07-01	Eculizumab (Biocad); BCD-148; eculizumab biosimilar (Russia market)	Complement C5 inhibitor	Rec humanized (hybrid IgG2/4) Fc-modified full mab. Biosimilar of Soliris (Alexion Pharmaceuticals)	Antibody	Biocad	Russian Federation	Cardiovascular, blood & acute care	Atypical hemolytic uremic syndrome (aHUS); paroxysmal nocturnal hemoglobinuria (PNH)	Market	
32522	2023-08-19	Veopoz; pozelimab-bbfg; REGN3918; REGN-3918	Complement C5 inhibitor	Rec fully human IgG4 monoclonal antibody (VelocImmune technology), SC and IV	Antibody	Regeneron Pharmaceuticals	United States	Cardiovascular, blood & acute care	Generalized myasthenia gravis (gMG) in combination with cemisiran after prior pozelimab monotherapy	III	
32521	2024-01-01	KP104; KP-104 (China study)	Complement factor C5 and factor H (CFH)	Rec bifunctional monoclonal antibody	Antibody	Kira Pharmaceuticals	United States	Cardiovascular, blood & acute care	Paroxysmal nocturnal hemoglobinuria (PNH)	II	

Search

Search

Any Word
  All Words
  Exact Phrase
  Advanced Search

Target: All Targets

Technology: ADC - Topoisomerase I Inhibitors

- All Technologies
- ADC - Auristatin
- ADC - Calicheamicin
- ADC - Doxorubicin
- ADC - Duocarmycin
- ADC - Maytansinoid
- ADC - Others
- ADC - Proteins & Peptides
- ADC - Pyrrolbenzodiazepine (PBD)
- ADC - SN-38 (irinotecan metabolite)
- ADC - Topoisomerase I Inhibitors**
- Agonist Antibodies
- Bispecific Antibodies
- Bispecific Proteins
- Camelid-derived Domain Antibodies
- Cell-Penetrating Antibodies, Proteins and Peptides
- Deimmunized Antibodies
- DNA Vaccines
- Fab or di-Fab Construct
- Fc-Fusion Protein

- Territory**
- All Countries
  - Aaland Islands
  - Afghanistan
  - Albania
  - Algeria
  - American Samoa
  - Andorra
  - Angola

- Therapeutic Area**
- All Therapeutic Areas
  - Cardiovascular, blood & acute care
  - Dermatology

- Phase**
- All Phases
  - Market
  - sBLA

Id	Las	Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33287	2024	nal antibody	Antibody	Perseus Therapeutics	United States	Dermatology	Prevention of hair loss in cancer	Preclinical	
33286	2024	nal antibody cytotoxic	Antibody	Cimeio Therapeutics	United States	Oncology	Hematologic malignancies in combination with CD45-engineered (shielded) hematopoietic stem cells (HSPCs)	Preclinical	
33285	2024	nal antibody conjugated to a merase I it with DAR of	Antibody	Pheon Therapeutics	United States	Oncology	Solid tumors	0	
33284	2024-06-20	BDC-4182	Rec humanized monoclonal antibody conjugated to TLR7/8 agonist	Bolt Biotherapeutics	United States	Oncology	Solid tumors	0	



Search

Print Export Export

Search

Clear

Any Word  All Words  Exact Phrase  Advanced Search

Target:

Technology:

- Territory**
- All Countries
  - Aaland Islands
  - Afghanistan
  - Albania
  - Algeria
  - American Samoa
  - Andorra
  - Angola

- Therapeutic Area**
- All Therapeutic Areas
  - Cardiovascular, blood & acute care
  - Dermatology

- Phase**
- All Phases
  - Market
  - sBLA

Id	Last Update	Project	Target	Class of Compound	Category	Company	Territory	Therapeutic Area	Indication	Phase	
33285	2024-06-20	PHN-010	Undisclosed novel target highly overexpressed in a wide range of solid tumors and DNA topoisomerase I inhibitor as cytotoxic payload	Rec monoclonal antibody conjugated to a novel topoisomerase I inhibitor agent with DAR of 8	Antibody	Pheon Therapeutics	United States	Oncology	Solid tumors	0	
33267	2024-06-17	Enhertu (US); fam-trastuzumab deruxtecan-nxki; DS-8201A	Her2 and topoisomerase I inhibitor	Rec monoclonal antibody conjugated via cleavable linker with novel topo I inhibitor DXd (exatecan derivative) (DAR 7-8)	Antibody	Daiichi Sankyo & AstraZeneca	Japan,United Kingdom	Oncology	HR positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (defined as IHC 0 with membrane staining [IHC >0 <1+]) advanced or metastatic breast cancer (DESTINY-Breast06 trial)	III	
33244	2024-04-13	GMAB ADC	Nucleoside transporter ENT2 (Equilibrative Nucleoside Transporter) for delivery of	Rec humanized variant V66 of lupus-derived, cell-penetrating, anti-DNA monoclonal antibody chemically linked to	Antibody	Gennaio Bio	United States	Oncology	Solid tumors	Preclinical	

Export Reports

Date:  to:  Custom Report Search Clear

Territory

- All Countries
- Aaland Islands
- Afghanistan
- Albania
- Algeria
- American Samoa
- Andorra
- Angola

Target:

All Targets

Technology:

All Technologies

Therapeutic Area

- All Areas
- Cardiovascular, blood & acute care
- Dermatology

Phase

- Ia
- II**
- Ib/II

Keyword

CD38

Any Word  All Words  Exact Phrase

Id	Project	Target	Class of Compound	Company	Category	Indication	R&D Stage	Message
19473	Modakafusp alfa; TAK-573; Anti-CD38-Attenukine	CD38 targeting and interferon alpha receptor	Rec fusion protein of IgG4 monoclonal antibody and attenuated (2 pt mutations) interferon alpha	Takeda Pharmaceutical (from Teva Pharmaceutical Industries)	Antibody	Relapsed/refractory multiple myeloma	II	
30175	Mezagitamab; TAK-079	CD38 (for CD38+ cell depletion)	Rec fully human, non-agonistic IgG1 cytolytic monoclonal antibody, SC	Takeda Pharmaceutical Co	Antibody	Generalized myasthenia gravis	II	
31274	Felzartamab; MOR202; MOR-202	Unique epitope on CD38	Rec fully human HuCAL mab	Biogen (acquired Human Immunology Biosciences, HI-Bio) (worldwide ex-Greater China rights from Morphosys)	Antibody	Anti-phospholipase A2 receptor autoantibody positive (anti-PLA2R+) membranous nephropathy (MN) (M-PLACE trial)	II	
31276	Felzartamab; MOR202; MOR-202	Unique epitope on CD38	Rec fully human HuCAL mab	Biogen (acquired Human	Antibody	Immunoglobulin A Nephropathy	II	

**Export Reports**

Date:  to:  Custom Report

- Territory**
- All Countries
  - Aaland Islands
  - Afghanistan
  - Albania
  - Algeria
  - American Samoa
  - Andorra
  - Angola

**Target:**  
All Targets

**Technology:**  
All Technologies

**Therapeutic Area**

- All Areas
- Cardiovascular, blood & ac
- Dermatology

**Phase**

- Ia
- II
- Ib/II

Id	Project	Target	Class of	Company	Therapeutic Area	Phase	Stage	Message
19473	Modakafusp alfa; TAK-573; Anti-CD38-Attenukine	CD38 targeting and interferon alpha receptor	Rec fusi monoclonal attenuate interferon					
30175	Mezagitamab; TAK-079	CD38 (for CD38+ cell depletion)	Rec fully human, non-agonistic IgG1 cytolytic monoclonal antibody, SC	Takeda Pharmaceutical Co	Generalized myasthenia gravis		II	
31274	Felzartamab; MOR202; MOR-202	Unique epitope on CD38	Rec fully human HuCAL mab	Biogen (acquired Human Immunology Biosciences, HI-Bio) (worldwide ex-Greater China rights from Morphosys)	Anti-phospholipase A2 receptor autoantibody positive (anti-PLA2R+) membranous nephropathy (MN) (M-PLACE trial)		II	
31276	Felzartamab; MOR202; MOR-202	Unique epitope on CD38	Rec fully human HuCAL mab	Biogen (acquired Human Immunology Biosciences, HI-Bio) (worldwide ex-Greater China rights from Morphosys)	Immunoglobulin A Nephropathy		II	

projects - Excel Ulrich Martin

Datei Start Einfügen Seitenlayout Formeln Daten Überprüfen Ansicht Hilfe Sie wünsch

Zwischenablage Schriftart Ausrichtung Zahl Bedingte Formatierung Als Tabelle formatieren Zellen Bearbeiten

A1 Id

A	B	C	D	E	F
1	Id	Project	Target	Class of Compound	Company
2	33155	CM313; CM-313	CD38	Rec humanized monoc	KeyMed Biosciences (IIT)
3	33153	Mezagitamab; TAK-0	CD38 (for CD38+ cell	Rec fully human, non-	Takeda Pharmaceutical (Antib
4	31276	Felzartamab; MOR202	Unique epitope on CD	Rec fully human HuCA	Biogen (acquired Human Antib
5	31274	Felzartamab; MOR202	Unique epitope on CD	Rec fully human HuCA	Biogen (acquired Human Antib
6	30175	Mezagitamab; TAK-0	CD38 (for CD38+ cell	Rec fully human, non-	Takeda Pharmaceutical (Antib
7	19473	Modakafusp alfa; TA	CD38 targeting and in	Rec fusion protein of I	Takeda Pharmaceutical (Antib
8					
9					
10					

Worksheet

Bereit Barrierefreiheit: Keine Probleme